Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Congenital Hyperinsulinism × 4-chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1 CNS 1

Conditions

Parkinson Disease 1 Neuroendocrine Tumors 1 Neuroblastoma 1 Lewy Body Disease 1 Congenital Hyperinsulinism 1 Brain Neoplasms 1

Interventions

fluorodopa F 18 2 Furosemide 1 4-chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04706910 2026-02-09

18F-DOPA II - PET Imaging Optimization

University of Alberta

Phase 3 Recruiting

CNSEndocrineNET

Brain Neoplasms, Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Lewy Body Disease, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon ⚡